ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p449.xmlThe Changing Face of Community Practice: The New Normal2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p449.pdf2026-04-18The Changing Face of Community Practice: The New Normalhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-pxxi.xmlNCCN News2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-pxxi.pdf2026-04-18NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-pxxxvi.xmlOncology Research Program2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-pxxxvi.pdf2026-04-18Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p455.xmlPart 2: Abstracts from the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p455.pdf2026-04-18Part 2: Abstracts from the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p465.xmlMultiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Review2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p465.pdf2026-04-18Multiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Reviewhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p451.xmlCorrespondence2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p451.pdf2026-04-18Correspondencehttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p452.xmlCorrespondence2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p452.pdf2026-04-18Correspondencehttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p473.xmlSoft Tissue Sarcoma, Version 2.20142026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p473.pdf2026-04-18Soft Tissue Sarcoma, Version 2.2014https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p542.xmlBreast Cancer Version 3.20142026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p542.pdf2026-04-18Breast Cancer Version 3.2014https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p527.xmlManagement of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p527.pdf2026-04-18Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markershttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p502.xmlAdvances in Supportive Care for Multiple Myeloma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p502.pdf2026-04-18Advances in Supportive Care for Multiple Myelomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p488.xmlSurvivorship: Pain Version 1.20142026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p488.pdf2026-04-18Survivorship: Pain Version 1.2014https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p513.xmlNeoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p513.pdf2026-04-18Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p599.xmlRenaming Ductal Carcinoma in Situ: Would Removing “Carcinoma” Reduce Overtreatment?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p599.pdf2026-04-18Renaming Ductal Carcinoma in Situ: Would Removing “Carcinoma” Reduce Overtreatment?https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p591.xmlPertuzumab in the Treatment of HER2+ Breast Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/12/4/article-p591.pdf2026-04-18Pertuzumab in the Treatment of HER2+ Breast Cancer